TriSalus Life Sciences, Inc. (TLSI): M&A transaction — TriSalus completes de-SPAC merger; FDA asks for additional PERIO-01 dose study

TriSalus Life Sciences, Inc.

Merger closed Aug 10, 2023; MTAC renamed TriSalus Life Sciences, trades on Nasdaq as TLSI and TLSIW.
Gross proceeds ~$42.9M from trust ($2.7M) and PIPE ($40.15M); ~$9.4M redeemed by MTAC stockholders.
Sponsor earnout shares subject to price milestones ($15-$30) over 5 years; lock-up 365 days or $12 trigger.
FDA acknowledged safety of SD-101 with PEDD but requires additional dose-optimization; NDA submission beyond 2025.
Co plans 40-50 patient study for PERIO-01; Phase 2 initiation targeted in 2023 but subject to change.

item 1.01 item 2.01 item 9.01 item 3.02 item 4.01 item 3.03 item 5.01 item 5.02 item 5.03 item 5.05 item 5.06 item 7.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TriSalus Life Sciences, Inc.: Approved and adopted a new Code of Business Conduct and Ethics (effective 2023-08-10).

Change: code of ethics
Effective: 2023-08-10

Exact text from the filing

on August 10, 2023, the New TriSalus Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of the Company

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TriSalus Life Sciences, Inc.: Filed Certificate of Incorporation with amendments proposed by Charter Proposal (effective 2023-08-10).

Change: charter amendment
Effective: 2023-08-10

Exact text from the filing

On August 10, 2023, the Company filed the Certificate of Incorporation with the Delaware Secretary of State

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TriSalus Life Sciences, Inc.: MTAC ceased to be a shell company as a result of the Business Combination (effective 2023-08-10).

Change: shell status
Effective: 2023-08-10

Exact text from the filing

MTAC ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TriSalus Life Sciences, Inc.: Adopted Amended and Restated Bylaws (effective 2023-08-10).

Change: bylaw amendment
Effective: 2023-08-10

Exact text from the filing

also adopted Amended and Restated Bylaws on August 10 , 2023 (the “Bylaws”), which replaced MTAC’s Amended and Restated Certificate of Incorporation and bylaws in effect as of such time

View on SEC.gov

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

TriSalus Life Sciences, Inc. underwent a change of control (closed 2023-08-10).

Action: change of control
Closing: 2023-08-10

Exact text from the filing

As a result of the consummation of the Business Combination, a change of control of MTAC has occurred, and the stockholders of MTAC as of immediately prior to the Closing held 9.7% of the outstanding shares of New TriSalus Common Stock immediately following the Closing.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-092586

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.